Old Antibacterial Drug Reborn as Potent Multi-Weapon Weapon Against Superbugs

In an era when antimicrobial resistance claims more than a million lives each year, scientists are increasingly turning to unexpected places for the next generation of antibiotics. A research team writing in the Journal of Advanced Research has now reported a striking example of chemical recycling: they took clofoctol, an antibacterial drug once prescribed in Europe for respiratory infections, and systematically rebuilt it into a cationic amphiphilic peptidomimetic capable of killing a broad range of dangerous bacteria. The effort produced a lead compound, designated compound 30, that in laboratory tests matched or exceeded the killing power of established antibiotics, showed little tendency to breed resistance, and cleared bacterial keratitis infections in mice as effectively as vancomycin and gatifloxacin.

The motivation behind the work lies in the arithmetic of the resistance crisis. In 2021, an estimated 4.71 million deaths worldwide were associated with bacterial antimicrobial resistance, including 1.14 million deaths directly attributable to it. Conventional antibiotics typically disable a single bacterial target, which means a single mutation can confer resistance. Newer strategies therefore seek agents that attack bacteria through several mechanisms at once, making it far harder for pathogens to survive. Antimicrobial peptides, the cationic membrane-attack molecules of the innate immune system, embody this philosophy, but their clinical use has been hampered by susceptibility to proteolysis, poor pharmacokinetics, and toxicity. Peptidomimetics, small molecules that mimic the architecture of these peptides, promise to retain their killing power while shedding their liabilities.

Clofoctol offered an unusually attractive starting point. Unlike generic hydrophobic scaffolds, it came with a documented history in humans: established pharmacokinetic behavior, pulmonary concentrations well above the levels needed to inhibit bacteria, and known effects on bacterial energy metabolism, including lowered intracellular ATP and disrupted membrane permeability. Its weaknesses were equally clear. It was essentially inactive against Gram-negative bacteria, poorly soluble in water, and potentially cytotoxic. Its precise molecular target had never been identified. Previous attempts to revive the drug had focused on reformulation and combination therapy, such as loading it into PLGA nanoparticles for lung delivery or pairing it with colistin against resistant Gram-negative pathogens. No one had yet redesigned the molecule itself.

The chemistry team, led by Jiayong Liu and colleagues, focused modifications on the phenolic hydroxyl group of clofoctol’s biphenyl scaffold, which defines the molecule’s hydrophobic domain. Through a modular synthetic route, they installed a library of cationic substituents, diethylamine groups, guanidinium groups, and chains of the amino acid arginine, connected by spacers of varying length. Each analogue was tested against a panel of Gram-positive and Gram-negative strains, including MRSA, Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, with minimum inhibitory concentrations measured by standardized broth microdilution and hemolysis assessed against rabbit red blood cells.

The structure–activity relationships that emerged were instructive. Simple alkyl appendages abolished activity entirely, confirming that positive charge is essential for electrostatic engagement with negatively charged bacterial membranes. Spacer length proved critical: a four-carbon linker balanced potency and selectivity, while longer or shorter chains degraded one or both. Among the cationic groups, arginine emerged as the star. Tri-arginine substitution with a C-terminal methyl ester produced compound 30, which inhibited Gram-positive bacteria at just 0.39 micrograms per milliliter, a fourfold improvement over clofoctol on a weight basis, and brought E. coli activity from greater than 50 micrograms per milliliter down to 1.56. Its hemolytic activity was undetectable even at 200 micrograms per milliliter, yielding a selectivity index exceeding 512.

Compound 30 also tackled some of the most feared hospital pathogens. It retained potency against carbapenem-resistant Enterobacterales strains of E. coli and Klebsiella at concentrations of 1.56 to 3.125 micrograms per milliliter, conditions under which amoxicillin was essentially inert. Quantitative analysis of the SAR data reinforced a key design principle: calculated lipophilicity correlated negatively with both potency and selectivity, meaning that simply making the molecule greasier did not help. Success required a calibrated balance of charge and hydrophobicity, precisely the balance that tri-arginine esterification achieved. The modification also cured clofoctol’s solubility problem; compound 30 remained clear in water at 100 milligrams per milliliter, a concentration at which the parent drug was visibly insoluble even at one-tenth that level.

Time-kill experiments revealed remarkably fast bactericidal kinetics. At eight times the MIC, compound 30 completely eradicated both S. aureus and E. coli cultures within one hour, whereas vancomycin needed far longer and amoxicillin required a full day. Serial passage experiments underscored another advantage: over 21 transfers, the compound’s MIC never shifted, while norfloxacin resistance in S. aureus rose 256-fold by day 11 and amoxicillin resistance in E. coli climbed 16-fold by day 16. The compound also throttled biofilms, reducing S. aureus biofilm formation by more than 93 percent at twice the MIC and dismantling 83 percent of established E. coli biofilms at four times the MIC. Activity remained stable under physiological salt concentrations, a hurdle that defeats many cationic antimicrobials.

Mechanistic probing pointed to membrane disruption as the best-supported component of the compound’s action. SYTOX Green uptake, NPN permeability assays, and Live/Dead staining all showed concentration-dependent compromise of bacterial membrane integrity, and compound 30 displaced a fluorescent probe from lipopolysaccharide, the anchor of the Gram-negative outer membrane, by more than 80 percent at twice the MIC. Additional effects layered on top of this primary mechanism. In a purified-enzyme assay, compound 30 inhibited E. coli topoisomerase IV-mediated DNA decatenation by 96 percent at twice the MIC, and molecular docking into the ATP-binding pocket of the ParE subunit yielded a plausible binding pose at −10.2 kilocalories per mole, although the authors caution that intracellular target engagement has not yet been demonstrated. Treatment also depleted intracellular ATP and triggered reactive oxygen species accumulation; adding the ROS scavenger N-acetylcysteine raised the compound’s MIC four- to eightfold, supporting a functional contribution of oxidative stress to bacterial killing.

Transcriptome sequencing of E. coli after two hours of exposure identified 129 differentially expressed genes among 4,491 analyzed, with enrichment in the tricarboxylic acid cycle, methionine biosynthesis, and fatty acid catabolism, a pattern consistent with the observed energy and redox disturbances. The authors are careful to frame these as treatment-associated cellular responses rather than proof of direct targets, and the hierarchy among membrane damage, metabolic collapse, oxidative stress, and topoisomerase inhibition remains to be causally disentangled. What is clear is that the compound engages bacteria on multiple fronts, which plausibly explains both its rapid killing and its stubborn refusal to select for resistance under laboratory conditions.

The in vivo results, though early-stage, provide the most compelling evidence yet that the strategy can translate. In a murine keratitis model, topical 0.5 percent compound 30 reduced corneal S. aureus burden by 4.65 log units, statistically indistinguishable from 5 percent vancomycin, and cut P. aeruginosa burden by 3.81 log units, comparable to 0.3 percent gatifloxacin. Ocular safety testing with fluorescein staining showed no corneal epithelial damage even at three times the therapeutic dose. The authors emphasize that considerable work remains before clinical development: pharmacokinetics, corneal penetration, metabolic stability, long-term repeat-dose safety, broader panels of clinical isolates, and the precise causal mechanisms all require further study. Still, the study demonstrates a principle with wide implications. Rather than designing peptide mimics from scratch or hunting for entirely new scaffolds, medicinal chemists can take clinically validated drugs, install the cationic amphiphilic features that make antimicrobial peptides lethal, and produce candidates that are soluble, selective, fast-acting, and resistance-resistant. As the pipeline of conventional antibiotics continues to run dry, that recipe may prove one of the most practical paths forward.

Subject of Research: Development of clofoctol-derived cationic amphiphilic peptidomimetics as multi-mechanism broad-spectrum antibacterial agents

Article Title: Clofoctol-derived amphiphilic peptidomimetics exhibit broadened antimicrobial activity via multiple contributing mechanisms

Article References: Liu, J., Lin, J.-H., Wang, W., Li, H., Zheng, Y., Zhang, Y., Chen, M., Zhong, R., Xing, C., Dang, Y., Chang, H., Liu, S., & Lin, S. (2026). Clofoctol-derived amphiphilic peptidomimetics exhibit broadened antimicrobial activity via multiple contributing mechanisms. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.09.007

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.09.007

Keywords: antimicrobial resistance, clofoctol, peptidomimetics, antibiotics, membrane disruption, MRSA, Gram-negative bacteria, biofilms, keratitis, drug discovery, topoisomerase IV, reactive oxygen species